Hormonal therapy: Current and new directions

Breast Journal

Volumn 9, Issue SUPPL. 1, 2003, Pages

  Ingle, James N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADVANCED CANCER; ARTHRALGIA; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENCY; FEMALE; FRACTURE; HORMONE DEFICIENCY; HOT FLUSH; HUMAN; MYALGIA; OSTEOPOROSIS; QUALITY OF LIFE; RISK FACTOR; VAGINA DISEASE;

EID: 0037263578     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.9.s1.4.x     Document Type: Conference Paper

References (24)

1. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol2001;19:881-94.
2. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-57.
3. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs anastrozole (Arimidex): second line treatment in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2001;21:34a.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-78.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
6. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
7. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol 2001;19:3817-27.
8. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
9. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or recombination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the randomised trial. Lancet 2002;359:2134-39.
10. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-27.
11. Ingle JN. Current status of adjuvant endocrine therapy for breast cancer. Clin Cancer Res 2001;7:S4392-96.
12. Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000;92:903-11.
13. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement. Results of the International Breast Cancer Study Group (IBCSG) Trial IV. Eur J Cancer 1998;34:632-40.
14. Ingle JN, Everson LK, Wieland HS, et al. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer 1989;63:1257-64.
15. Dowsett M, Doody D, Miall S, et al. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 1998;56:25-34.
16. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial 53. Lancet 1998;352:98-101.
17. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 1998;352:93-97.
18. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
19. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized trial. Lancet 2002;360:817-24.
20. Gross P, Grynpas M, Qi S, Hu H. The effects of exmestame on bone lipids in the ovariectomized rat. Breast Cancer Res Treat 2001;69:224.
21. O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-61.
22. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14.
23. Ganz PA, Desmond KA, Belin TR, et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999;17:2371-80.
24. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18:743-53.